Evidence map›Paper›PMID 26360259›Full record

ArticlePloS one2015

Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.

Masako Nishizawa, Masakazu Matsuda, Junko Hattori, Teiichiro Shiino, Tetsuro Matano, Walid Heneine, Jeffrey A Johnson, Wataru Sugiura

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Masako NishizawaAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Masakazu MatsudaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Junko HattoriClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Teiichiro ShiinoInfectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan.
Tetsuro MatanoAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.
Walid HeneineDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Jeffrey A JohnsonDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Wataru SugiuraAIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan; Department of AIDS Research, Nagoya University Graduate School of Medicine, Nagoya, Japan.
National Institute of Infectious Diseases · JPCenters for Disease Control and Prevention · USNagoya Medical Center · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug-resistant HIV are more prevalent and persist longer than previously demonstrated by bulk sequencing due to the ability to detect low-frequency variants. To clarify a clinical benefit to monitoring minority-level drug resistance populations as a guide to select active drugs for salvage therapy, we retrospectively analyzed the dynamics of low-frequency drug-resistant population in antiretroviral (ARV)-exposed drug resistant individuals. MATERIALS AND

methodsSix HIV-infected individuals treated with ARV for more than five years were analyzed. These individuals had difficulty in controlling viremia, and treatment regimens were switched multiple times guided by standard drug resistance testing using bulk sequencing. To detect minority variant populations with drug resistance, we used a highly sensitive allele-specific PCR (AS-PCR) with detection thresholds of 0.3-2%. According to ARV used in these individuals, we focused on the following seven reverse transcriptase inhibitor-resistant mutations: M41L, K65R, K70R, K103N, Y181C, M184V, and T215F/Y. Results of AS-PCR were compared with bulk sequencing data for concordance and presence of additional mutations. To clarify the genetic relationship between low-frequency and high-frequency populations, AS-PCR amplicon sequences were compared with bulk sequences in phylogenetic analysis.

resultsThe use of AS-PCR enabled detection of the drug-resistant mutations, M41L, K103N, Y181C, M184V and T215Y, present as low-frequency populations in five of the six individuals. These drug resistant variants persisted for several years without ARV pressure. Phylogenetic analysis indicated that pre-existing K103N and T215I variants had close genetic relationships with high-frequency K103N and T215I observed during treatment. DISCUSSION AND

conclusionOur results demonstrate the long-term persistence of drug-resistant viruses in the absence of drug pressure. The rapid virologic failures with pre-existing mutant viruses detectable by AS-PCR highlight the clinical importance of low-frequency drug-resistant viruses. Thus, our results highlight the usefulness of AS-PCR and support its expanded evaluation in ART clinical management.

Indexed as

Antiretroviral Therapy, Highly ActiveDrug Resistance, ViralAllelesCD4 Lymphocyte CountGenotypeHIV-1HIV InfectionsHomosexuality, MaleHumansJapanMaleMedication AdherenceMutationMutation RatePhylogenyPolymerase Chain Reaction

Identifiers

PMID26360259
PMCPMC4567277
OpenAlexW2248458737

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.